Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 20656 AL 20670

Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder

Nakhal MM, Aburuz S, Sadek B, Akour A.

Molecules. 2022 Oct 23;27(21):7174. doi: 10.3390/molecules27217174.

Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases

Teixeira MI, Lopes CM, Amaral MH, Costa PC.

Colloids Surf B Biointerfaces. 2023 Jan;221:112999. doi: 10.1016/j.colsurfb.2022.112999. Epub 2022 Nov 2.

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp KO, Glotfelty EJ, Li Y, Greig NH.

Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.

Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease

Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY.

Neuroscience. 2022 Dec 15;507:139-148. doi: 10.1016/j.neuroscience.2022.11.001. Epub 2022 Nov 11.

[Role of β2-Adrenergic Receptor Agonist in the Cognitive Impairment Associated with Neurodegenerative Diseases]

Wang ZJ, Guo WN, Guo QZ, Wang S, Wang TJ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Dec;44(6):1112-1116. doi: 10.3881/j.issn.1000-503X.14469.

The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases

Amanollahi M, Jameie M, Heidari A, Rezaei N.

Mol Neurobiol. 2023 Feb;60(2):923-959. doi: 10.1007/s12035-022-03102-z. Epub 2022 Nov 16.

Applications of nanobodies in brain diseases

Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, Raes G.

Front Immunol. 2022 Nov 8;13:978513. doi: 10.3389/fimmu.2022.978513. eCollection 2022.

Introduction: Unraveling the complex contributions of indigenous microbes to neurological health and disease

Sampson TR.

Int Rev Neurobiol. 2022;167:xi-xvi. doi: 10.1016/S0074-7742(22)00138-6.

Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?

Guidetti M, Bertini A, Pirone F, Sala G, Signorelli P, Ferrarese C, Priori A, Bocci T.

Int J Mol Sci. 2022 Nov 9;23(22):13775. doi: 10.3390/ijms232213775.

Lead-induced neurodevelopmental lesion and epigenetic landscape: Implication in neurological disorders

Liu M, Liu R, Wang R, Ba Y, Yu F, Deng Q, Huang H.

J Appl Toxicol. 2023 Sep;43(9):1256-1271. doi: 10.1002/jat.4419. Epub 2022 Dec 13.

Emerging Roles for the RNA-Binding Protein HuD (ELAVL4) in Nervous System Diseases

Silvestri B, Mochi M, Garone MG, Rosa A.

Int J Mol Sci. 2022 Nov 23;23(23):14606. doi: 10.3390/ijms232314606.

Tau Isoforms: Gaining Insight into MAPT Alternative Splicing

Corsi A, Bombieri C, Valenti MT, Romanelli MG.

Int J Mol Sci. 2022 Dec 6;23(23):15383. doi: 10.3390/ijms232315383.

The Role of Ketogenic Diet in the Treatment of Neurological Diseases

Dyńka D, Kowalcze K, Paziewska A.

Nutrients. 2022 Nov 24;14(23):5003. doi: 10.3390/nu14235003.

The Effects of Dietary Interventions on Brain Aging and Neurological Diseases

Lobo F, Haase J, Brandhorst S.

Nutrients. 2022 Nov 30;14(23):5086. doi: 10.3390/nu14235086.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias